Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Pflow is a revolutionary, disposable, and portable home based urine flow measurement test
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Harnessing advanced data analysis for early detection, prevention and better outcomes
Subscribe To Our Newsletter & Stay Updated
